Therapy: Spleen tyrosine kinase inhibitors-novel therapies for RA?

Nature Reviews Rheumatology

Volumn 7, Issue 3, 2011, Pages 134-136

  Gómez Puerta, José A ^a   Bosch, Xavier ^b  

^a Department of Rheumatology   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOSTAMATINIB; PLACEBO; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR;

DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; NAUSEA; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; TREATMENT OUTCOME;

EID: 79952455930     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.8     Document Type: Short Survey

References (10)

1. Weinblatt, M. E. et al. An oral spleen tyrosine kinase (syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303-1312 (2010).
2. Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: a twelve? week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309-3318 (2008).
3. Genovese, M. C et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum. doi:10.1002/art.30114.
4. Mcinnes, I. B. & O'Dell, J. R. state of the art: rheumatoid arthritis. Ann. Rheum. Dis. 69, 1898-1906 (2010).
5. RiccAboni, M., Bianchi, I. & Petrillo, P spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov. Today 15, 517-530 (2010).
6. Bajpai, M., Chopra, P, Dastidar, S. G. & Ray, A. spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin. Investig. Drugs 17, 641-659 (2008). (Pubitemid 351843609)
7. Bahjat, F. R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine upus Arthritis Rheum. 58, 1433-1444 (2008). (Pubitemid 351705932)
8. Pine, P R. et al. inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel syk inhibitor. Clin. Immunol. 124, 244-257 (2007). (Pubitemid 47247604)
9. Rivera, J. & Colbert, R. A. Healing the syk through kinase inhibitors. N. Engl. J. Med. 363, 1362-1364 (2010)
10. Jabbour, e., Deininger, M. & Hochhaus, A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia doi:10.1038/leu.2010.215.